# Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial

> Research article (The Lancet Diabetes & Endocrinology, 2025) · cited 18× · AI/ML

**Wikidata**: [openalex:W4406788765](https://www.wikidata.org/wiki/openalex:W4406788765)  
**Source**: https://4ort.xyz/entity/lerodalcibep-and-evolocumab-for-the-treatment-of-homozygous-familial-hypercholesterolaemia-with-pcsk9-inhibition-liberat